A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: Continuous spikes and waves during sleep is definitely a target
Abstract Although LVT is currently extensively prescribed in childhood epilepsy, its effect on the panel of refractory epilepsy syndromes has not been entirely evaluated prospectively. In order to study the efficacy and safety of LVT as adjunctive therapy according to syndromes, we included 102 pati...
Gespeichert in:
| Veröffentlicht in: | Seizure (London, England) England), 2011-05, Vol.20 (4), p.320-325 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 325 |
|---|---|
| container_issue | 4 |
| container_start_page | 320 |
| container_title | Seizure (London, England) |
| container_volume | 20 |
| creator | Chhun, S Troude, P Villeneuve, N Soufflet, C Napuri, S Motte, J Pouplard, F Alberti, C Helfen, S Pons, G Dulac, O Chiron, C |
| description | Abstract Although LVT is currently extensively prescribed in childhood epilepsy, its effect on the panel of refractory epilepsy syndromes has not been entirely evaluated prospectively. In order to study the efficacy and safety of LVT as adjunctive therapy according to syndromes, we included 102 patients with refractory seizures (6 months to 15 years) in a prospective open-labeled trial. The responder rate was respectively 36% and 32% at 3 and 6 months with 6% and 7% patients becoming seizure free. Among the responders at 6 months ( n = 33), seizure frequency decreased by 66% and 79% at 3 and 6 months LVT compared to baseline. The highest benefit was for CSWS patients with 2/3 responders, 50% seizure free and no aggravation. LVT provided respectively 39% and 42% responders in focal and absence epilepsies. Infantile spasms and Dravet syndrome experienced the lowest efficacy. No patient with myoclonic-astatic epilepsy or Lennox–Gastaut syndrome was aggravated. LVT dose over 40 mg/kg/d was associated with a lower response rate. Tolerability was excellent. In spite of a small sample, we assume that CSWS is a good candidate for a randomized-controlled trial with LVT. |
| doi_str_mv | 10.1016/j.seizure.2010.12.017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_861792974</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1059131111000070</els_id><sourcerecordid>861792974</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-86c55dae79e591bb39c1dcc7e8438d3f9828fdba6e14ef5a237bb10e5eea8bfb3</originalsourceid><addsrcrecordid>eNqFUsuO1DAQjBCIXRY-AeQbpwxu580BtBrxklbiAJwtx-4snnWcYDuzCt_BB9PRDBy4cHLbqupuV1WWPQe-Aw71q8Muov25BNwJvr2JHYfmQXYJVSFyUbftQ6p51eVQAFxkT2I8cM67EorH2YUAUdVNwy-zX9dsDlOcUSd7RDbN6HOnenRoWApWOXZv03fm8IjJBqUxqZFZz2Y0VhFAM5ytwzmuLK7ehGnE-JrtJ5-sX6YlsjjbO4xMecPu1ZEqswTrb1l0iDOzdMfBepvQrUyxpMItpqfZo0G5iM_O51X27f27r_uP-c3nD5_21ze5Lus65W2tq8oobDqsOuj7otNgtG6wLYvWFEPXinYwvaoRShwqJYqm74FjhajafuiLq-zlqS9J8GPBmORoo0bnlEfaXbY1NJ3ompKQ1QmpSawYcJBzsKMKqwQuNz_kQZ79kJsfEoQkP4j34jxh6Uc0f1l_DCDA2xMA6Z9Hi0FGbdFrkjeQJ9JM9r8j3vzTQTsSVCt3hyvGw7QETyJKkJEI8ssWii0TAJQHTiv8BnUauMs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>861792974</pqid></control><display><type>article</type><title>A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: Continuous spikes and waves during sleep is definitely a target</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Chhun, S ; Troude, P ; Villeneuve, N ; Soufflet, C ; Napuri, S ; Motte, J ; Pouplard, F ; Alberti, C ; Helfen, S ; Pons, G ; Dulac, O ; Chiron, C</creator><creatorcontrib>Chhun, S ; Troude, P ; Villeneuve, N ; Soufflet, C ; Napuri, S ; Motte, J ; Pouplard, F ; Alberti, C ; Helfen, S ; Pons, G ; Dulac, O ; Chiron, C</creatorcontrib><description>Abstract Although LVT is currently extensively prescribed in childhood epilepsy, its effect on the panel of refractory epilepsy syndromes has not been entirely evaluated prospectively. In order to study the efficacy and safety of LVT as adjunctive therapy according to syndromes, we included 102 patients with refractory seizures (6 months to 15 years) in a prospective open-labeled trial. The responder rate was respectively 36% and 32% at 3 and 6 months with 6% and 7% patients becoming seizure free. Among the responders at 6 months ( n = 33), seizure frequency decreased by 66% and 79% at 3 and 6 months LVT compared to baseline. The highest benefit was for CSWS patients with 2/3 responders, 50% seizure free and no aggravation. LVT provided respectively 39% and 42% responders in focal and absence epilepsies. Infantile spasms and Dravet syndrome experienced the lowest efficacy. No patient with myoclonic-astatic epilepsy or Lennox–Gastaut syndrome was aggravated. LVT dose over 40 mg/kg/d was associated with a lower response rate. Tolerability was excellent. In spite of a small sample, we assume that CSWS is a good candidate for a randomized-controlled trial with LVT.</description><identifier>ISSN: 1059-1311</identifier><identifier>EISSN: 1532-2688</identifier><identifier>DOI: 10.1016/j.seizure.2010.12.017</identifier><identifier>PMID: 21256770</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adolescent ; Anticonvulsants - pharmacokinetics ; Anticonvulsants - therapeutic use ; Child ; Child, Preschool ; Continuous slow waves during sleep ; Epilepsy - drug therapy ; Epilepsy syndrome ; Female ; Humans ; Infant ; Levetiracetam ; Male ; Neurology ; Piracetam - analogs & derivatives ; Piracetam - pharmacokinetics ; Piracetam - therapeutic use ; Prospective trial ; Sleep - drug effects ; Sleep - physiology</subject><ispartof>Seizure (London, England), 2011-05, Vol.20 (4), p.320-325</ispartof><rights>British Epilepsy Association</rights><rights>2011 British Epilepsy Association</rights><rights>Copyright © 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-86c55dae79e591bb39c1dcc7e8438d3f9828fdba6e14ef5a237bb10e5eea8bfb3</citedby><cites>FETCH-LOGICAL-c466t-86c55dae79e591bb39c1dcc7e8438d3f9828fdba6e14ef5a237bb10e5eea8bfb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.seizure.2010.12.017$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21256770$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chhun, S</creatorcontrib><creatorcontrib>Troude, P</creatorcontrib><creatorcontrib>Villeneuve, N</creatorcontrib><creatorcontrib>Soufflet, C</creatorcontrib><creatorcontrib>Napuri, S</creatorcontrib><creatorcontrib>Motte, J</creatorcontrib><creatorcontrib>Pouplard, F</creatorcontrib><creatorcontrib>Alberti, C</creatorcontrib><creatorcontrib>Helfen, S</creatorcontrib><creatorcontrib>Pons, G</creatorcontrib><creatorcontrib>Dulac, O</creatorcontrib><creatorcontrib>Chiron, C</creatorcontrib><title>A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: Continuous spikes and waves during sleep is definitely a target</title><title>Seizure (London, England)</title><addtitle>Seizure</addtitle><description>Abstract Although LVT is currently extensively prescribed in childhood epilepsy, its effect on the panel of refractory epilepsy syndromes has not been entirely evaluated prospectively. In order to study the efficacy and safety of LVT as adjunctive therapy according to syndromes, we included 102 patients with refractory seizures (6 months to 15 years) in a prospective open-labeled trial. The responder rate was respectively 36% and 32% at 3 and 6 months with 6% and 7% patients becoming seizure free. Among the responders at 6 months ( n = 33), seizure frequency decreased by 66% and 79% at 3 and 6 months LVT compared to baseline. The highest benefit was for CSWS patients with 2/3 responders, 50% seizure free and no aggravation. LVT provided respectively 39% and 42% responders in focal and absence epilepsies. Infantile spasms and Dravet syndrome experienced the lowest efficacy. No patient with myoclonic-astatic epilepsy or Lennox–Gastaut syndrome was aggravated. LVT dose over 40 mg/kg/d was associated with a lower response rate. Tolerability was excellent. In spite of a small sample, we assume that CSWS is a good candidate for a randomized-controlled trial with LVT.</description><subject>Adolescent</subject><subject>Anticonvulsants - pharmacokinetics</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Continuous slow waves during sleep</subject><subject>Epilepsy - drug therapy</subject><subject>Epilepsy syndrome</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Levetiracetam</subject><subject>Male</subject><subject>Neurology</subject><subject>Piracetam - analogs & derivatives</subject><subject>Piracetam - pharmacokinetics</subject><subject>Piracetam - therapeutic use</subject><subject>Prospective trial</subject><subject>Sleep - drug effects</subject><subject>Sleep - physiology</subject><issn>1059-1311</issn><issn>1532-2688</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsuO1DAQjBCIXRY-AeQbpwxu580BtBrxklbiAJwtx-4snnWcYDuzCt_BB9PRDBy4cHLbqupuV1WWPQe-Aw71q8Muov25BNwJvr2JHYfmQXYJVSFyUbftQ6p51eVQAFxkT2I8cM67EorH2YUAUdVNwy-zX9dsDlOcUSd7RDbN6HOnenRoWApWOXZv03fm8IjJBqUxqZFZz2Y0VhFAM5ytwzmuLK7ehGnE-JrtJ5-sX6YlsjjbO4xMecPu1ZEqswTrb1l0iDOzdMfBepvQrUyxpMItpqfZo0G5iM_O51X27f27r_uP-c3nD5_21ze5Lus65W2tq8oobDqsOuj7otNgtG6wLYvWFEPXinYwvaoRShwqJYqm74FjhajafuiLq-zlqS9J8GPBmORoo0bnlEfaXbY1NJ3ompKQ1QmpSawYcJBzsKMKqwQuNz_kQZ79kJsfEoQkP4j34jxh6Uc0f1l_DCDA2xMA6Z9Hi0FGbdFrkjeQJ9JM9r8j3vzTQTsSVCt3hyvGw7QETyJKkJEI8ssWii0TAJQHTiv8BnUauMs</recordid><startdate>20110501</startdate><enddate>20110501</enddate><creator>Chhun, S</creator><creator>Troude, P</creator><creator>Villeneuve, N</creator><creator>Soufflet, C</creator><creator>Napuri, S</creator><creator>Motte, J</creator><creator>Pouplard, F</creator><creator>Alberti, C</creator><creator>Helfen, S</creator><creator>Pons, G</creator><creator>Dulac, O</creator><creator>Chiron, C</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110501</creationdate><title>A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: Continuous spikes and waves during sleep is definitely a target</title><author>Chhun, S ; Troude, P ; Villeneuve, N ; Soufflet, C ; Napuri, S ; Motte, J ; Pouplard, F ; Alberti, C ; Helfen, S ; Pons, G ; Dulac, O ; Chiron, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-86c55dae79e591bb39c1dcc7e8438d3f9828fdba6e14ef5a237bb10e5eea8bfb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Anticonvulsants - pharmacokinetics</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Continuous slow waves during sleep</topic><topic>Epilepsy - drug therapy</topic><topic>Epilepsy syndrome</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Levetiracetam</topic><topic>Male</topic><topic>Neurology</topic><topic>Piracetam - analogs & derivatives</topic><topic>Piracetam - pharmacokinetics</topic><topic>Piracetam - therapeutic use</topic><topic>Prospective trial</topic><topic>Sleep - drug effects</topic><topic>Sleep - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chhun, S</creatorcontrib><creatorcontrib>Troude, P</creatorcontrib><creatorcontrib>Villeneuve, N</creatorcontrib><creatorcontrib>Soufflet, C</creatorcontrib><creatorcontrib>Napuri, S</creatorcontrib><creatorcontrib>Motte, J</creatorcontrib><creatorcontrib>Pouplard, F</creatorcontrib><creatorcontrib>Alberti, C</creatorcontrib><creatorcontrib>Helfen, S</creatorcontrib><creatorcontrib>Pons, G</creatorcontrib><creatorcontrib>Dulac, O</creatorcontrib><creatorcontrib>Chiron, C</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seizure (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chhun, S</au><au>Troude, P</au><au>Villeneuve, N</au><au>Soufflet, C</au><au>Napuri, S</au><au>Motte, J</au><au>Pouplard, F</au><au>Alberti, C</au><au>Helfen, S</au><au>Pons, G</au><au>Dulac, O</au><au>Chiron, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: Continuous spikes and waves during sleep is definitely a target</atitle><jtitle>Seizure (London, England)</jtitle><addtitle>Seizure</addtitle><date>2011-05-01</date><risdate>2011</risdate><volume>20</volume><issue>4</issue><spage>320</spage><epage>325</epage><pages>320-325</pages><issn>1059-1311</issn><eissn>1532-2688</eissn><abstract>Abstract Although LVT is currently extensively prescribed in childhood epilepsy, its effect on the panel of refractory epilepsy syndromes has not been entirely evaluated prospectively. In order to study the efficacy and safety of LVT as adjunctive therapy according to syndromes, we included 102 patients with refractory seizures (6 months to 15 years) in a prospective open-labeled trial. The responder rate was respectively 36% and 32% at 3 and 6 months with 6% and 7% patients becoming seizure free. Among the responders at 6 months ( n = 33), seizure frequency decreased by 66% and 79% at 3 and 6 months LVT compared to baseline. The highest benefit was for CSWS patients with 2/3 responders, 50% seizure free and no aggravation. LVT provided respectively 39% and 42% responders in focal and absence epilepsies. Infantile spasms and Dravet syndrome experienced the lowest efficacy. No patient with myoclonic-astatic epilepsy or Lennox–Gastaut syndrome was aggravated. LVT dose over 40 mg/kg/d was associated with a lower response rate. Tolerability was excellent. In spite of a small sample, we assume that CSWS is a good candidate for a randomized-controlled trial with LVT.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>21256770</pmid><doi>10.1016/j.seizure.2010.12.017</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1059-1311 |
| ispartof | Seizure (London, England), 2011-05, Vol.20 (4), p.320-325 |
| issn | 1059-1311 1532-2688 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_861792974 |
| source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Anticonvulsants - pharmacokinetics Anticonvulsants - therapeutic use Child Child, Preschool Continuous slow waves during sleep Epilepsy - drug therapy Epilepsy syndrome Female Humans Infant Levetiracetam Male Neurology Piracetam - analogs & derivatives Piracetam - pharmacokinetics Piracetam - therapeutic use Prospective trial Sleep - drug effects Sleep - physiology |
| title | A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: Continuous spikes and waves during sleep is definitely a target |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T12%3A00%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prospective%20open-labeled%20trial%20with%20levetiracetam%20in%20pediatric%20epilepsy%20syndromes:%20Continuous%20spikes%20and%20waves%20during%20sleep%20is%20definitely%20a%20target&rft.jtitle=Seizure%20(London,%20England)&rft.au=Chhun,%20S&rft.date=2011-05-01&rft.volume=20&rft.issue=4&rft.spage=320&rft.epage=325&rft.pages=320-325&rft.issn=1059-1311&rft.eissn=1532-2688&rft_id=info:doi/10.1016/j.seizure.2010.12.017&rft_dat=%3Cproquest_cross%3E861792974%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=861792974&rft_id=info:pmid/21256770&rft_els_id=S1059131111000070&rfr_iscdi=true |